Caliway Biopharmaceuticals Co (TPE:6919) Beneish M-Score: 699.98 (As of Sep. 01, 2026) — 300% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6919 Caliway Biopharmaceuticals Co Ltd TPE:6919
55 GF Score
Price NT$94.80
GF Value NT$59.03
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Caliway Biopharmaceuticals Co Beneish M-Score?

Caliway Biopharmaceuticals Co TPE:6919 -4.82% 55 Beneish M-Score is 699.98 as of Sep. 01, 2026, which is 300% above its 10-year median of 174.92. GuruFocus rates TPE:6919 with a GF Score™ of 55/100 and a GF Value™ of NT$59.03 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 832 Biotechnology companies, Caliway Biopharmaceuticals Co ranks worse than 99.76% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 699.98 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Caliway Biopharmaceuticals Co's Beneish M-Score or its related term are showing as below:

TPE:6919' s Beneish M-Score Range Over the Past 10 Years
Min: -3.56   Med: 174.92   Max: 699.98
Current: 699.98

During the past 7 years, the highest Beneish M-Score of Caliway Biopharmaceuticals Co was 699.98. The lowest was -3.56. And the median was 174.92.


Caliway Biopharmaceuticals Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Caliway Biopharmaceuticals Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caliway Biopharmaceuticals Co Beneish M-Score Chart

Caliway Biopharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 -2.98 586.28

Caliway Biopharmaceuticals Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.48 351.99 586.28 606.88 699.98

TPE:6919 vs VRTX, REGN, MRNA: Beneish M-Score Comparison

For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Caliway Biopharmaceuticals Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Caliway Biopharmaceuticals Co's Beneish M-Score falls into.


TPE:6919
55GF Score
Caliway Biopharmaceuticals Co Ltd TPE:6919
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caliway Biopharmaceuticals Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Caliway Biopharmaceuticals Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0+0.528 * 0.985+0.404 * 1743.2362+0.892 * 0.6556+0.115 * 2.1245
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6735+4.679 * 0.002458-0.327 * 2.1184
=699.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Total Receivables was NT$0.00 Mil.
Revenue was 3.566 + 0.002 + 12.41 + 13.415 = NT$29.39 Mil.
Gross Profit was 2.327 + 0.001 + 9.007 + 9.327 = NT$20.66 Mil.
Total Current Assets was NT$4,198.29 Mil.
Total Assets was NT$9,430.86 Mil.
Property, Plant and Equipment(Net PPE) was NT$152.54 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$31.06 Mil.
Selling, General, & Admin. Expense(SGA) was NT$71.53 Mil.
Total Current Liabilities was NT$69.93 Mil.
Long-Term Debt & Capital Lease Obligation was NT$98.34 Mil.
Net Income was -222.516 + -107.754 + 80.19 + -7.73 = NT$-257.81 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0.00 Mil.
Cash Flow from Operations was -129.103 + -22.671 + -60.995 + -68.222 = NT$-280.99 Mil.
Total Receivables was NT$0.21 Mil.
Revenue was 12.212 + 0 + 9.363 + 23.257 = NT$44.83 Mil.
Gross Profit was 8.186 + 0 + 6.847 + 16.008 = NT$31.04 Mil.
Total Current Assets was NT$9,443.31 Mil.
Total Assets was NT$9,499.91 Mil.
Property, Plant and Equipment(Net PPE) was NT$53.67 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$30.11 Mil.
Selling, General, & Admin. Expense(SGA) was NT$162.01 Mil.
Total Current Liabilities was NT$80.01 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 29.393) / (0.205 / 44.832)
=0 / 0.004573
=0

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(31.041 / 44.832) / (20.662 / 29.393)
=0.692385 / 0.702956
=0.985

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4198.291 + 152.539) / 9430.858) / (1 - (9443.306 + 53.672) / 9499.91)
=0.53866 / 0.000309
=1743.2362

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=29.393 / 44.832
=0.6556

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(30.107 / (30.107 + 53.672)) / (31.056 / (31.056 + 152.539))
=0.359362 / 0.169155
=2.1245

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(71.532 / 29.393) / (162.006 / 44.832)
=2.433641 / 3.613624
=0.6735

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((98.343 + 69.932) / 9430.858) / ((0 + 80.013) / 9499.91)
=0.017843 / 0.008423
=2.1184

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-257.81 - 0 - -280.991) / 9430.858
=0.002458

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Caliway Biopharmaceuticals Co has a M-score of 699.98 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 699.98 mean?
Caliway Biopharmaceuticals Co (TPE:6919) has a Beneish M-Score of 699.98 as of Sep. 01, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Caliway Biopharmaceuticals Co and its competitors. This is 300% above median its historical median of 174.92. According to the industry distribution chart, Caliway Biopharmaceuticals Co ranks #830 out of 832 companies in the Biotechnology industry, placing it in the top 99.8%.
Is Caliway Biopharmaceuticals Co's Beneish M-Score too high?
Caliway Biopharmaceuticals Co's current Beneish M-Score of 699.98 is 300% above median its 10-year median of 174.92. Based on the distribution chart, Caliway Biopharmaceuticals Co ranks #830 out of 832 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caliway Biopharmaceuticals Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caliway Biopharmaceuticals Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Caliway Biopharmaceuticals Co ranks #830 out of 832 companies for Beneish M-Score. This places Caliway Biopharmaceuticals Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Caliway Biopharmaceuticals Co and its competitors. Caliway Biopharmaceuticals Co's current Beneish M-Score is 699.98, which is 300% above median its own 10-year median of 174.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliway Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co (TPE:6919) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$59.03, compared to a current price of NT$94.80 — trading 60.6% above its estimated fair value. The current Beneish M-Score is 699.98, which is 300% above median its 10-year median of 174.92. Caliway Biopharmaceuticals Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Caliway Biopharmaceuticals Co (TPE:6919), the current Beneish M-Score is 699.98 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caliway Biopharmaceuticals Co (TPE:6919) Overvalued in 2026?

Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co stock appears to be overvalued. The current stock price of NT$94.80 is trading 60.6% above its estimated GF Value™ of NT$59.03. GuruFocus considers Caliway Biopharmaceuticals Co to be Significantly Overvalued.

Key valuation signals for TPE:6919:

  • Beneish M-Score: 699.98 (300% above median its 10-year median of 174.92)
  • GF Value™: NT$59.03 vs. price of NT$94.80 (60.6% above fair value)
  • GF Score™: 55/100 with 8 warning signs

No single metric tells the full story. See the TPE:6919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Caliway Biopharmaceuticals Co Business Description

Address No.99, Section 1, Xintai 5th Road, 32rd Floor-9, Xizhi District, New Taipei City, TWN, 221
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. The group has one operating segment, which is Healthy Food, and others.
55GF Score

Get the complete analysis for TPE:6919

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$94.80
Price
NT$59.03
GF Value